CB Issuance Amendment: Conversion Price Adjusted
애드바이오텍
179530
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2767
Risk-adjusted indicator based on 2767 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • New Conversion Price: 2,522 KRW/Share (Previously 2,021 KRW/Share)
- • Shares Issuable from New CB: 2,180,808 Shares (Previously 2,721,425 Shares)
- • Dilution Rate (New CB only): 7.49% (Previously 9.17%)
- • Total Potential Dilution (All CBs): 30.98% (Previously 32.99%)
- • New CB Principal: 5.5B KRW
AI Analysis Summary
ADBIOTECH Co.,Ltd. has amended its Material Fact Report regarding the issuance of convertible bonds. The conversion price for the new CB has been adjusted upwards from 2,021 KRW/Share to 2,522 KRW/Share. This adjustment reduces the number of shares issuable from the new CB from 2,721,425 shares to 2,180,808 shares, consequently lowering the potential dilution rate for the new CB from 9.17% to 7.49%. The total potential dilution from all outstanding and new CBs combined is now 30.98% of the currently issued shares (26,950,299 shares), down from 32.99%. While the higher conversion price is generally positive, the overall impact remains dilutive.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.